Methanesulfonyl chloride → HCID 58529554, 화합물
반응식
[CH2:1]([C:8]1[S:9][C:10]2[CH:16]=[CH:15][C:14]([C:17]3[CH:18]=[C:19]([CH:27]4[CH2:32][CH2:31][NH:30][CH2:29][CH2:28]4)[N:20]4[C:25]=3[C:24]([NH2:26])=[N:23][CH:22]=[N:21]4)=[CH:13][C:11]=2[N:12]=1)[C:2]1[CH:7]=[CH:6][CH:5]=[CH:4][CH:3]=1.[CH3:33][S:34](Cl)(=[O:36])=[O:35]>>[CH2:1]([C:8]1[S:9][C:10]2[CH:16]=[CH:15][C:14]([C:17]3[CH:18]=[C:19]([CH:27]4[CH2:32][CH2:31][N:30]([S:34]([CH3:33])(=[O:36])=[O:35])[CH2:29][CH2:28]4)[N:20]4[C:25]=3[C:24]([NH2:26])=[N:23][CH:22]=[N:21]4)=[CH:13][C:11]=2[N:12]=1)[C:2]1[CH:3]=[CH:4][CH:5]=[CH:6][CH:7]=1참가 물질
3
실험 절차
In a manner similar to the procedure described for the preparation of Example 331 and using 5-(2-benzyl-1,3-benzothiazol-5-yl)-7-piperidin-4-ylpyrrolo[2,1-f][1,2,4]triazin-4-amine and methanesulfonyl chloride as starting material, 20 mg (34%) of the desired product was isolated. 1H NMR (400 MHz, CD2Cl2) δ 8.49 (s, 1H), 8.39 (d, 1H), 8.32 (s, 1H), 7.92 (d, 1H), 7.84-7.78 (m, 5H), 7.04 (s, 1H), 4.91 (s, 2H), 4.38-4.33 (m, 2H), 3.84-3.78 (m, 1H), 3.38-3.30 (m, 2H), 3.23 (s, 3H), 2.74-2.69 (m, 2H), 2.38-2.30 (m, 2H); LC-MS m/z [M+H]+ 519.2, RT 3.13 min.
후처리
- customIn a manner similar to the procedure described for the preparation of Example 331